© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

Treatment News
Refined Mapping of HIV’s Reservoir Could Aid in Cure Research
PrEP Truvada blue pills
Truvada Tied to Changes in Gut-Based Immunity
group of people coughing virus sick
What’s New in COVID-19 Research?

Switching to Biktarvy Is a Success for African Americans With HIV

Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.
Remdesivir production.

FDA Approves Remdesivir for Hospitalized COVID-19 Patients

The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
Antibodies binding to protein

Trogarzo Maintains Viral Load Suppression for Nearly 10 Years

Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.
Colorized scanning electron micrograph of a cell isolated from a patient that is heavily infected with SARS-CoV-2 virus particles (orange/red).

SARS-CoV-2 May Use Key Carbohydrate to Infect Cells

A carbohydrate called heparan sulfate, found on cell surfaces, may help the new coronavirus infects cells.

Diabetes Linked to Advanced Liver Damage in People With HIV

A recent study also found that having a higher body mass index was associated with a higher risk of fatty liver disease.

MUST read

Gene Editing Delays Viral Rebound During HIV Treatment Interruption
a US dollar symbol in a life preserver
Some People With HIV Don’t Adhere to Treatment to Save Money
There’s Never Been a Better Time to Get Pregnant If One of You Has HIV
POZ March 2019 cover U=U Undetectable = Untransmitable
Communicating Undetectable Equals Untransmittable
The Science Is Clear: With HIV, Undetectable Equals Untransmittable
4 in 5 HIV Transmissions Likely Come From Those Not in Care for the Virus
Remdesivir production.

Remdesivir for COVID-19 Shows No Survival Benefit in Large Study

None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.

Switching HIV Regimen to Biktarvy Is Safe and Effective for the Long Term

Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
Novel coronavirus SARS-CoV-2

NIH Study Aims To Identify Promising COVID-19 Treatments for Larger Trials

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

Among Older Men, HIV Is Linked to Higher Dementia Risk

A recent study of veterans found that antiretroviral treatment was not associated with a mitigated dementia risk.

Hot topics

#Cure
#Long-Term Survivors
Ounce of Prevention sign against a blue sky
#Prevention
PrEP written on a chalkboard
#PrEP

Kaletra Still Shows No Benefit for COVID-19

The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
HPV vaccine

HPV Vaccine Greatly Lowers Risk of Invasive Cervical Cancer

Compared with unvaccinated women, the risk among women vaccinated before age 17 dropped by almost 90%.

Switching HIV Meds to Long-Acting Cabenuva May Not Require Oral Lead-In

A clinical trial found no difference in outcomes based on whether participants switching to Cabenuva first took oral meds for four weeks.

HIV Regimen of Islatravir and Pifeltro Doesn’t Appear to Affect Kidney Function

A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.
Advertisement
Features
Newsfeed

Hot topics

Forums: Support and discussion
Blogs: The community speaks
POZ Stories: Get inspired
Magazine: Search the archives
HIV: The Basics
Recursos de VIH/SIDA en Español
AIDS Is Everyday
Ask POZ